BRD4 PROTAC Degrader and Fulvestrant Sensitivity in ER+ Breast Cancer

Integrated ChIP-seq analysis reveals substantial co-occupancy of BRD4 and estrogen receptor on shared pathways. The dataset, authored by Xiulei Zhang and last updated in May 2026, likely contains results from experiments assessing a PROTAC-targeted BRD4 degrader's effect on fulvestrant sensitivity in breast cancer cells. It identifies GREB1 as a key super-enhancer-associated effector regulated by BRD4.

Use Cases

• Identify co-occupied genomic regions of BRD4 and ER based on integrated ChIP-seq analysis mentioned in the description
• Model the relationship between BRD4 expression and clinical outcomes in ER+ breast cancer patients based on the described findings
• Investigate GREB1 signaling disruption as a mechanism for enhanced drug sensitivity based on the described working model

Strengths

• Dataset is 5.6 MB in size, indicating a focused and manageable scale for analysis.
• Published under a permissive CC-BY-4.0 license, allowing for broad reuse and sharing.
• Description provides a detailed methodological background including ChIP-seq and cell-based assays.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment for large-scale modeling.
• Data may reflect experimental bias inherent to the specific cell line and assay conditions used.

Provenance

Source

figshare, author Xiulei Zhang

Collection Method

Likely contains experimental results from ChIP-seq analysis, cell-based antitumor efficacy assays, and clinical outcome correlation.

Freshness

Last updated 2026-05-19 04:21:00; freshness should be verified.